Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121881 | 0.91 | BRAF (0.67) | EGFRKDRBRAFFLT3MAPK14 | |
| SCHEMBL426005 | 0.91 | EGFR (0.57) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL10160948 | 0.90 | EGFR (0.56) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL425677 | 0.90 | EGFR (0.56) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL13622708 | 0.88 | EGFR (0.56) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL10160950 | 0.87 | EGFR (0.53) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL428513 | 0.87 | EGFR (0.53) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL10160951 | 0.86 | EGFR (0.54) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL426640 | 0.86 | EGFR (0.54) | EGFRKDRBRAFFLT3EHMT2 | |
| SCHEMBL13759061 | 0.85 | EHMT2 (0.54) | EGFRKDRBRAFFLT3EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2007100759-A2 | METHOD FOR TREATING COMMON VARIABLE IMMUNODEFICIENCY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | EGFR 2725/4885KDR 3240/4885BRAF 3320/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | EGFR 3409/4885KDR 3480/4885BRAF 4124/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | EGFR 4490/4885KDR 4489/4885BRAF 892/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | EGFR 4490/4885KDR 4489/4885BRAF 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.